SERB Pays $800m For Boston Scientific Specialty Pharma Business

Device Maker Acquired The Drugs In $4.2bn BTG Buy Last Year

The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.

Group of paper plane in one direction and with one individual pointing in the different way
Boston Scientific's sale of BTG Specialty Pharmaceuticals was anticipated when it bought BTG plc for $4.2bn • Source: Shutterstock

Stark International Lux SARL and SERB SAS, affiliates of Brussels-based SERB Specialty Pharmaceuticals, will pay $800m in cash for Boston Scientific's BTG Specialty Pharmaceuticals business. 

The deal announced on 1 December is worth about four times the business’s annual revenue and will close during the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.